Food for Thought, page-20

I get what you are saying about the disappointment with current revenue and share price. But a 'current share price' in most stocks usually reflects much more than current earnings. The share price should also reflect future earnings growth. In the case of Clinuvel this includes the potential for vitiligo, the lotions, dna repair, and even stroke. As such, I think Clinuvel is being undervalued to an extraordinary degree compared to many other companies, since I don't think the current share price is taking those into account account at all. Unless you do not believe Clinuvel will be successful with Vitiligo, and their other products. Again, they don't have to be making current revenue from them to benefit the share price. The market just needs to realize a decent probably of their success and then assign it a value or make a forward multiple adjustment to the current price. At some point, I believe the shorters are going to be in for a rude awakening.